Obstet Gynecol. 2011 Aug;118(2 Pt 1):405-410. doi: 10.1097/AOG.0b013e31822c99af.
The past two decades have yielded profound advances in the fields of prenatal diagnosis and fetal intervention. Although fetal interventions are driven by a beneficence-based motivation to improve fetal and neonatal outcomes, advancement in fetal therapies raises ethical issues surrounding maternal autonomy and decision making, concepts of innovation versus research, and organizational aspects within institutions in the development of fetal care centers. To safeguard the interests of both the pregnant woman and the fetus, the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics make recommendations regarding informed consent, the role of research subject advocates and other independent advocates, the availability of support services, the multidisciplinary nature of fetal intervention teams, the oversight of centers, and the need to accumulate maternal and fetal outcome data.
在过去的二十年中，产前诊断和胎儿干预领域取得了深远的进展。尽管胎儿干预是基于改善胎儿和新生儿结局的善意动机，但胎儿治疗的进步引发了围绕产妇自主性和决策、创新与研究的概念以及胎儿护理中心发展中的机构组织方面的伦理问题。为了维护孕妇和胎儿的利益，美国妇产科医师学会和美国儿科学会就知情同意、研究对象倡导者和其他独立倡导者的作用、支持服务的可用性、胎儿干预团队的多学科性质、中心的监督以及积累母婴结局数据的必要性提出了建议。
